البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
ZOLEDRONIC ACID (ZOLEDRONIC ACID HEMIPENTAHYDRATE)
BAUSCH HEALTH, CANADA INC.
M05BA08
ZOLEDRONIC ACID
4MG
SOLUTION
ZOLEDRONIC ACID (ZOLEDRONIC ACID HEMIPENTAHYDRATE) 4MG
INTRAVENOUS
100
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0141761002; AHFS:
APPROVED
2021-09-16
_ _ PRODUCT MONOGRAPH PR VAL-ZOLEDRONIC ACID Zoledronic Acid for Injection 4 mg zoledronic acid /5 mL (incorporated as the hemipentahydrate) concentrate solution for intravenous infusion in prefilled syringe STERILE CONCENTRATE / MUST BE DILUTED BEFORE USE BONE METABOLISM REGULATOR BAUSCH HEALTH, CANADA INC DATE OF REVISION: 2150 St-Elzear Blvd. West September 14, 2021 Laval, Quebec H7L 4A8 Control #: 255538 _Pr_ _VAL-ZOLEDRONIC ACID Product Monograph Page 2 of 54_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ..................................................................................................12 DRUG INTERACTIONS ..................................................................................................21 DOSAGE AND ADMINISTRATION ..............................................................................21 OVERDOSAGE ................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ............................................................26 STORAGE AND STABILITY ..........................................................................................31 SPECIAL HANDLING INSTRUCTIONS .......................................................................31 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................32 PART II: SCIENTIFIC INFORMATION ...............................................................................33 PHARMACEUTICAL INFORMATION ....... اقرأ الوثيقة كاملة